Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BXBaudax Bio, Inc. logo

Baudax Bio, Inc. (BXRXQ)

Other OTC · Currency in USD
$0.00 ▲ +0.00 (+0.00%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$0.00
Open
$0.00
Day's Range
$0.00 – $0.00
52 Week Range
$0.00 – $0.00
Volume
1
Avg. Volume
3,759
Market Cap
$4.36K
Beta (5Y Monthly)
9.54
PE Ratio (TTM)
--
EPS (TTM)
-$177.30
Earnings Date
Nov 11, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Baudax Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
9
CEO
Gerri Henwood

Baudax Bio, Inc., a biotechnology company, develops and commercializes products for hospital and other acute care related settings. The company develops T cell receptor, that focus on immune modulating therapies for orphan diseases or complications associated with such diseases, as well as the treatment of autoimmune disorders. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies.

Earnings

Next report: Wed, Nov 11, 2026
EPS estimate -$270.67 · Revenue est. $500.00K
DateEst.Actual
Aug 16, 2023-$2.04-$1.49Beat
May 12, 2023$5.75$4.91Miss

Analyst view

Rating: Hold
Buy 0% · Hold 100% · Sell 0%

Get free alerts on BXRXQ and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.